Background Inhaled antibiotics are standard of care for persons with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infection. APT-1026 (levofloxacin inhalation solution, LIS) is fluoroquinolone in development. We compared the safety and efficacy of LIS to tobramycin inhalation solution (TIS) in persons ≥12 years old with CF and chronic P. aeruginosa infection.
INTRODUCTION
Cystic fibrosis (CF) is characterized by chronic respiratory tract infection with multiple bacterial species, including Pseudomonas aeruginosa [1] . Chronic P. aeruginosa infection is associated with accelerated progression of lung disease, increased morbidity, and decreased survival [2] [3] [4] .
Inhaled antipseudomonal antibiotics are standard therapy to suppress infection, reduce risk of pulmonary exacerbations, improve quality of life, and preserve lung function in CF patients chronically infected with P. aeruginosa [5, 6] . Approved inhalational antibiotics for use in people with CF and chronic P. aeruginosa infection in the EU are tobramycin, colistimethate, and aztreonam, and in the US are tobramycin and aztreonam (e-supplement for approved product names).
There is need for additional safe and effective inhaled antibiotics. The prevalence of chronic P. aeruginosa infection increases about 3% per year of age [7] , with >70% chronically infected by adulthood [8] . As median predicted survival for CF has exceeded 40 years of age [8] , adherence to consensus treatment guidelines [5, 6] will result in many patients being treated for decades with inhaled antibiotics.
There is evidence that the FEV 1 response to aerosolized tobramycin becomes attenuated in individuals with CF after exposure of more than 6 months [9, 10] , a phenomenon that cannot be fully accounted for by selection of bacterial populations with decreased in vitro tobramycin susceptibilities [9] . Similar attenuation of efficacy may occur for other inhaled antibiotics [11] .
In addition, patient intolerance to some inhaled antibiotic formulations can be substantial [12, 13] . Thus, there is a need for additional options, including alternate classes of antibiotics, to treat patients who are intolerant or have developed attenuated response and to allow for rotation of therapies to reduce the emergence of antimicrobial ineffectiveness [14] Fluoroquinolones have high potency and broad spectrum of bactericidal activity and so are attractive to develop as inhaled therapy for CF. APT-1026 (levofloxacin inhalation solution, LIS; also formerly known as MP-376) [15] is the first inhaled solution form of a fluoroquinolone intended for use in chronic maintenance therapy. We describe the results of a phase 3 study designed to compare the efficacy and safety of LIS with tobramycin inhalation solution (TIS) when administered over multiple cycles in individuals with CF and chronic P. aeruginosa infection who had previously used inhaled tobramycin.
METHODS

Study Design
This was a randomized, open-label, parallel group, active comparator trial conducted at 125 CF centers in Europe, USA, and Israel. Subjects were recruited between Feb 2011 and Aug 2012. Eligible patients were randomized 2:1 to three 28 days on/28 days off treatment cycles of LIS 240 mg (2.4 mL of a 100 mg of levofloxacin per ml as APT-1026) twice daily (BID) or TIS 300 mg (5 mL) BID (TOBI ® , Novartis Pharmaceuticals Corp.), with seven study visits 28 days apart ( Figure 1 ). TIS was delivered with a PARI LC ® Plus nebulizer with compressor as indicated in the prescribing information, and LIS was delivered with the PARI investigational eFlow ® nebulizer. Comparison to the approved licensed therapy and delivery device is mandated by the European Medicine Agency for approval of a new inhaled antibiotic for CF [16] .
Subjects and study coordinators were aware of the treatment assignment, but the site investigators and medical monitors remained blinded in order to minimize treatment bias during the study.
The study was conducted in accordance with Good Clinical Practice, as recommended by 
Endpoints
The primary efficacy endpoint was the relative change in FEV 1 percent predicted from baseline to day 28. The trial was designed as a non-inferiority study in accordance with guidance published by the EMA [16] . Additional endpoints included change in other spirometry
) from baseline to day 28, time to pulmonary exacerbation, time to administration of antipseudomonal antibiotics other than Study Drug, change from baseline in CF Questionnaire-Revised (CFQ-R) respiratory symptom score [18] , and change from baseline in sputum P. aeruginosa density (log 10 colony-forming units (CFU)
per gram sputum). Lung function was compared between treatment groups after only 28 days to reduce the probability that concomitant antibiotic treatment for pulmonary exacerbation would confound analyses. A pulmonary exacerbation was defined per protocol as a patient experiencing change in >4 of 12 concurrent signs or symptoms [19] regardless of decision to treat with an antibiotic. An independent blinded adjudication board reviewed all instances in which patients received additional antipseudomonal antibiotics but did not meet the protocol definition of an acute exacerbation to determine if these treatments were associated with exacerbation (further description in e-supplement). Adverse events and serious adverse events were captured from baseline to the final visit for each patient.
Throat swabs or sputum were collected at all study visits (except visit 4/day 84) for selective bacterial culture and in vitro susceptibility testing by central laboratories. Distinct P.
aeruginosa morphotypes from patients were analyzed separately. Bacterial densities in sputum specimens were determined by dilution plating.
Statistics
Statistical analysis was performed on the intention to treat (ITT) population consisting of all randomized patients. The primary non-inferiority endpoint of relative change in FEV 1 percent predicted from baseline to day 28 was assessed with an analysis of covariance (ANCOVA) model including fixed effects for treatment group and the stratification binary variables of geographic region, age and baseline FEV 1 percent predicted. If the lower boundary of the 2-sided 95% confidence interval (CI) for the treatment difference (LIS-TIS) was > −4% (prespecified non-inferiority margin), non-inferiority of LIS to TIS was concluded. The prospective analysis plan dictated that if non-inferiority of LIS to TIS was demonstrated, a subsequent assessment of superiority was to be performed using a 2-sided test for difference at a 5% level of significance.
The sample size was based on a 4% non-inferiority margin, an 18% SD in relative change from baseline in FEV 1 percent predicted, and a 10% discontinuation rate over the first 28 days of the study. A sample size of 267 patients randomized 2:1 to LIS and TIS, respectively, was selected to provide 90% power with a 2-sided 5% significance level based on an assumption that LIS was 4 percentage points better than TIS.
Time to pulmonary exacerbation and time to treatment were analyzed by Cox proportional hazard method, with statistical significance determined by stratified log-rank test.
There was no alpha adjustment for multiple testing for the other efficacy variables. P-values from these tests were considered to be descriptive only and were evaluated for nominal significance only (i.e., whether ≤0.05). Levofloxacin and tobramycin minimum inhibitory concentrations (MIC) were determined using broth dilution reference methods as published by the Clinical Laboratory Standards Institute (CLSI; REF-M100). Changes in the levofloxacin MIC were evaluated as the proportion of patients for which the levofloxacin MIC of their most resistant P. aeruginosa isolate changed by >2 fold (the limit of sensitivity of dilution testing) from baseline to the end of the study using a 2-sided Fisher's exact test with a 5% significance level. [20] RESULTS Two hundred and eighty two patients were randomized in this study; 189 to receive LIS and 93 TIS, with 272 available for safety evaluation (Figure 2 ). Baseline characteristics of the groups were similar (Table 1) . At the randomization visit, P. aeruginosa and Staphylococcus aureus were isolated in 93% and 47% of patients, respectively (P. aeruginosa was isolated from all patients at the screening visit as per inclusion criterion). There were no differences in baseline P. aeruginosa antibiotic susceptibility patterns between the two groups (e-supplement Table 1 ). Concomitant medications were also similar between the two groups at baseline (esupplement Table 2 ). The median number of the inhaled antibiotic courses during the previous year was 5 and 44% of the enrolled patients had received 6 or more courses.
Efficacy
The study met the primary endpoint of non-inferiority in relative change in FEV 1 percent predicted from day 0 to day 28. The least squares (LS) mean between-group difference (LIS minus TIS) in FEV 1 was 1.86% [95% CI -0.66 to 4.39%]. As non-inferiority of LIS was demonstrated, a subsequent assessment of superiority was performed. The difference between the LS means for relative change in FEV 1 percent predicted at day 28 between LIS and TIS was not statistically significant (2.24%, p=0.15; Figure 3 ; e-supplement Table 3 ). A pre-planned analysis of categorical change in FEV 1 percent predicted from baseline to day 28 showed improvement for 70% of patients receiving LIS compared to 53% of patients receiving TIS (p = 0.02) Similar trends were seen for FVC and FEF 25-75 (e-supplement Tables 4 and 5) .
Time to exacerbation, additional antibiotic requirement and hospitalisation.
The time to first exacerbation was not significantly different in the LIS group (median 131 days) compared to the TIS group (median 90.5 days) (HR = 0.78; 95% CI: 0.57 to 1.07, p=0.15; Figure 4 ). The median time to administration of antibiotics was 141 days for LIS and 110 days for TIS(HR = 0.73; 95% CI: 0.53 to 1.01; p = 0.04 by stratified log rank test). The proportion of patients hospitalized for a respiratory exacerbation over the 168 day study period was significantly lower in the LIS group than the TIS group (17.5% versus 28.0%, p = 0.04).
CFQ-R Respiratory Domain
Scores in the respiratory domain of the CFQ-R were similar at baseline. The LS means increased (i.e. improvement) in the LIS group and decreased in the TIS group at day 28 (3.19 units, p = 0.05; e-supplement Figure 1) . The results are similar between the two groups at the end of the study.
Microbiology
Both treatments reduced sputum P. aeruginosa density, with the magnitude of reduction greater for TIS than LIS, although the difference in change from baseline to day 28 was not significantly different (LS mean difference 0.44 log 10 CFU/g; 95% CI -0.01 to 0.88). P.
aeruginosa densities increased during the subsequent period off treatment. Over the course of the study, the proportion of patients who experienced a >2-fold increase in the levofloxacin MIC of their most levofloxacin-resistant P. aeruginosa isolate was similar in the two treatment groups (21% for LIS versus 17% for TIS; p = 0.5) (e-supplement Figure 2 ). No significant emergence of other bacterial opportunists was observed in either treatment group during the study.
Safety
Discontinuations from the study (Figure 2 ) and the occurrence of treatment emergent adverse events (TEAEs; Table 2 ) were similar between the two groups. Treatment emergent serious adverse events (SAEs) were reported for 22.0% of LIS and 32.2% of TIS patients.
Excluding disease progression, treatment-emergent SAEs were reported for 7.7% of LIS patients and for 14.4% of TIS patients during the entire study. There was a higher incidence of dysgeusia (taste distortion) in patients treated with LIS which accounted for the higher incidence of TEAEs reported in >5% of patients (Table 2 ). During the treatment periods, the TEAEs other than dysgeusia that were reported for at least 5% more LIS patients than TIS patients were cough, increased sputum, paranasal sinus hypersecretion, and headache. Fluoroquinolone class effects associated with systemic administration, such as nausea, arthralgia and tendonitis were uncommon in this study. The incidence of arthralgia was low and similar between treatment groups (5.5% LIS, 5.6% TIS), and there were few cases of arthropathy and arthritis/osteoarthritis in the LIS group. One LIS patient had an SAE of costochondritis that led to discontinuation of study drug and resolved after treatment. One LIS patient had symptoms consistent with tendonitis but there were no reports of tendon rupture.
DISCUSSION
The study demonstrates that LIS is not inferior to TIS in the treatment of patients with CF (Figure 4 ), the differences between treatments were not significant.
Additionally, respiratory symptoms measured by the CFQ-R respiratory domain improved for LIS patients compared to those receiving TIS (e-supplement Figure 1 ).
TIS and LIS both reduced the sputum density of P. aeruginosa. In addition, there were no clinically relevant changes in MICs to either drug during the study. Previous placebocontrolled studies of inhaled antibiotics have noted an association between mean antimicrobial effect (measured by change in bacterial density) and mean lung function benefit [9, 21] .
However, while there was a numerically greater mean antimicrobial effect among patients treated with TIS (Figure 3) , there was a numerically greater change in FEV 1 for those treated with LIS, suggesting there is not a simple relationship between the two measures.
Pulmonary exacerbations are frequent and important events for patients with CF [22] . In this study, no difference was observed between the two groups in the occurrence of pulmonary exacerbations, even when including the adjudicated results of those patients treated with systemic antimicrobial agents but not meeting the protocol-defined signs or symptoms of an exacerbation. There was a significantly different incidence of hospitalizations between groups, which was lower in the LIS group compared to TIS. Taken together these suggest a benefit in reduction of exacerbations from treatment with LIS (as has previously been shown for TIS [9] ).
There was a significant benefit in CFQ-R respiratory domain scores for patients treated with LIS compared to TIS. However the patterns of response in this measure were unusual compared to other inhaled antibiotic studies. In previous trials, mean improvements in CFQ-R respiratory domain scores during treatment waned when off therapy. In this study, there was a general improvement in the CFQ-R score in the LIS group throughout the trial, whereas there flume desktop 19/10/2014 15:30
Deleted: but was little effect in the TIS group. The explanation for these changes is not clear from our data, but may reflect the higher incidence of pulmonary exacerbations in the TIS treated group.
One of the objectives of this study was to assess the safety of LIS compared to TIS, a therapy recommended in CFF and ECFS pulmonary guidelines [5, 6] and used over many years [23] . Overall the safety profile of LIS was similar to that of TIS. The most notable difference in safety profiles was the higher incidence of taste distortion in patients receiving LIS, but this did not appear to have an impact on adherence to the regimen. The inclusion criteria requiring a history of TIS use offers a distinct advantage to TIS with respect to tolerability; patients who could not tolerate TIS would not have participated. The previously reported rate of taste perversion for TIS was 6.6%.
There are some limitations to the design and interpretation of this study. The first is that the subjects were not blinded to treatment assignment because of differences in nebulizers used for LIS and TIS administration. Despite an effort to reduce bias by attempting to keep the investigators blinded to treatment assignment, it was not possible to do this for study
participants. An active comparator was employed to study LIS because of the regulatory requirements to provide data on the noninferiority of LIS compared to the current standard of care for inhaled antibiotic therapy, TIS, over an extended period [16] . The regulatory requirements also necessitated the use of different delivery devices. Whereas it might be perceived that the faster nebulizer might be preferable (i.e. favoring LIS), the choice of the nebulizer would not favor one drug over the other for the primary endpoint (i.e. FEV 1 ). It is acknowledged that patients, and possibly investigators, were aware of the treatment allocation in this study, and perhaps this may have influenced patient care and the assessment of subjective outcomes, such as the diagnosis and treatment of pulmonary exacerbations or patient quality of life. Such biases might have an impact on the subjective endpoints, but we believe are unlikely to have affected objective endpoints (e.g. FEV 1 ) in this study. Deleted: the An additional limitation was that patients had a substantial treatment experience with inhaled tobramycin. On the one hand this might favour the efficacy findings toward LIS, given the possibility of an attenuated response to TIS over time. On the other hand, there was a likely selection for pre-existing TIS tolerance in this population, so we might expect fewer discontinuations in the TIS group. However, we can also presume a considerable treatment experience with systemic fluoroquinolones in this population, given the substantial use of fluoroquinolones for the treatment of CF pulmonary exacerbations [24] and the levofloxacin susceptibilities of P. aeruginosa isolated from patients at baseline of this study (e-supplement Table 1 ).
In conclusion, LIS has been shown to be non-inferior to TIS in people with CF chronically infected with P. aeruginosa. There was no significant difference in time to first exacerbation between the two groups but there was significant improvement in quality of life assessed by CFQ-R respiratory scores, and a nominally significant reduction in respiratory- 
